Business Wire

CA-BERKELEY-SKYDECK

2.8.2022 13:02:06 CEST | Business Wire | Press release

Share
Berkeley SkyDeck Introduces New Tracks Ahead of Open Applications for Next Cohort Class

Berkeley SkyDeck , the global hub for entrepreneurship and leading accelerator, today announced that applications are now open for its 15th cohort class, with a final deadline of August 31, 2022. Applications are available here . Batch 15 cohorts can take advantage of new tracks added in the last year, including the Aero-Astro Track, led by advisor Robin Riedel of McKinsey and Company, and the Blockchain/Crypto Track, led by advisor Linda Kreitzman. Berkeley SkyDeck’s Chip Track also named a new advisor, David Horsley of UC Davis. In addition, Berkeley SkyDeck will launch a CivTech Track in the coming year, in partnership with the Center for Security in Politics at UC Berkeley, with former Secretary of Homeland Security Janet Napolitano leading the track as a primary advisor. In addition to these new tracks, SkyDeck will continue to work with startups in industries that have always been an area of focus for venture investors, including consumer, enterprise software, biotech, greentech and more.

Berkeley SkyDeck accepts just over 1.5% of startups that apply and approximately 20 to 25 startups overall for each of its cohorts. Cohort companies receive $200,000 in funding, $750,000 worth of free and discounted resources, and access to SkyDeck’s unsurpassed network of UC Berkeley alumni, faculty, and advisors. Alumni of Berkeley SkyDeck have enjoyed great success in their respective industries, collectively raising more than $1.7 billion in funding. The recently launched Berkeley SkyDeck Europe is currently working with its first group of cohorts, who will present their own Demo Day on October 20, 2022.

“Our mission at Berkeley SkyDeck is to continue the tradition of excellence in entrepreneurship and innovation that makes UC Berkeley one of the top public universities in the world. Expanding our operations in Europe and opening additional tracks for our cohorts are just a couple examples of how we are striving to meet the needs of founders around the world,” said Caroline Winnett, Executive Director. “I am looking forward to seeing what these batch applicants have to offer – and how we can leverage the university’s vast resources to set them up for success.”

Berkeley SkyDeck’s newest tracks reflect trends in growth and investments. Last year, for example, aerospace startups raised $15.4 billion while US semiconductor and chip investment reached $2.6 billion in 2021 , nearly doubling in just three years. Civtech is also burgeoning, with the industry’s transaction volume rising to $14 billion total in 2021 .

“While Berkeley SkyDeck might be rooted here in Silicon Valley, our reach is global, and we’re excited to see how both homegrown and international startups tackle the issues in their industries across all of our tracks,” said Chon Tang, Founding Partner, Berkeley SkyDeck Fund. “As we evaluate, advise, and potentially invest, we are continually energized by these fresh ideas and new approaches. The SkyDeck Fund is ready and waiting to take these newest cohort companies to the next level.”

In March 2022, Berkeley SkyDeck recently announced the close of the $60 million SkyDeck Fund II, which continues to actively fund companies. The SkyDeck Fund has invested in 160 companies to date, representing a wide range of businesses and industries, from 30 countries around the world. Unlike other VC funds, the SkyDeck Fund shares half of its profits with UC Berkeley, helping to continue the university’s mission of delivering excellence in education.

Berkeley SkyDeck will conduct extensive research on applicants, and will hold interviews between September and October 2022. The six-month program will begin in November 2022, concluding at the end of April 2023. Berkeley SkyDeck will host the cohort’s Demo Day for investors on April 4, 2023.

About Berkeley SkyDeck

Berkeley SkyDeck is a leading accelerator and the global hub for entrepreneurship. As UC Berkeley’s largest and most prominent accelerator, SkyDeck combines hands-on mentorship with the vast resources of its research university. SkyDeck is the only accelerator of its kind that offers the value of a dedicated investment fund alongside the resources and network of a top university. To date, SkyDeck startups have raised more than $1.7 billion in aggregate. Participating startups have access to SkyDeck’s 420 advisors, 70 industry partners, and a network of more than 510,000 UC Berkeley alumni. For more information, see skydeck.berkeley.edu .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye